SCHEMBL5520562

SCHEMBL5520562

CN(C)c1cccc2c1-c1ccccc1C2O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.47
ALDH1A1 P00352 4/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
NSD2 O96028 1/20 0.47
EGFR P00533 1/20 0.47
LMNA P02545 1/20 0.47
MAPK1 P28482 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
PDK2 Q15119 1/20 0.46
KDM4E B2RXH2 3/20 0.43
KMT2A Q03164 3/20 0.39
TP53 P04637 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
MEN1 O00255 2/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
HSD17B10 Q99714 1/20 0.39
GPR3 P46089 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2362367 0.79 GPR3 (0.42) MAPTALDH1A1L3MBTL1NSD2EGFR
Hydrochloric Acid SCHEMBL7192917 0.77 MAPT (0.46) MAPTALDH1A1L3MBTL1NSD2EGFR
SCHEMBL8750096 0.76 HTR2B (0.51) MAPTALDH1A1PDK2KDM4EKMT2A
SCHEMBL28172796 0.73 MAOA (0.43) MAPTALDH1A1EGFRLMNAMAPK1
SCHEMBL29884836 0.71 MAOA (0.52) MAPTALDH1A1KDM4EKMT2ATP53
SCHEMBL216862 0.71 MAOA (0.52) MAPTALDH1A1KDM4EKMT2ATP53
SCHEMBL29376368 0.71 MAOA (0.52) MAPTALDH1A1KDM4EKMT2ATP53
SCHEMBL26465909 0.70 KDM4E (0.54) MAPTALDH1A1L3MBTL1LMNAPDK2
SCHEMBL5523779 0.70 PGR (0.44) MAPTALDH1A1PDK2KDM4EKMT2A
SCHEMBL5576934 0.70 MAPT (0.59) MAPTALDH1A1L3MBTL1NSD2EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070254889-A1 Compounds and methods useful for rescuing cells from beta-amyloid toxicity and treatment of Alzheimer's disease THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA 2007-11-01 US disclosed
US-20050271584-A1 Biphenyls and fluorenes as imaging agents in alzheimer's disease THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2005-12-08 US disclosed
US-20050214222-A1 In vivo imaging of amyloid plaques in glaucoma using intravenous injectable dyes NATIONAL INSTITUTES OF HEALTH-DIRECTOR DEITR 2005-09-29 US disclosed
EP-1553985-A2 BIPHENYLS AND FLUORENES AS IMAGING AGENTS IN ALZHEIMER'S DISEASE The Trustees of The University of Pennsylvania (US) 2005-07-20 EP disclosed
WO-2004032975-A2 BIPHENYLS AND FLUORENES AS IMAGING AGENTS IN ALZHEIMER'S DISEASE THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2004-04-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254889-A1 Compounds and methods useful for rescuing cells from beta-amyloid toxicity and treatment of Alzheimer's disease APP, BACE1, IAPP MAPT 13/4885ALDH1A1 1209/4885L3MBTL1 1784/4885
US-20050271584-A1 Biphenyls and fluorenes as imaging agents in alzheimer's disease APP, BACE2, BACE1 MAPT 4/4885ALDH1A1 1533/4885L3MBTL1 1900/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.